Targeting 4-1BB for tumor immunotherapy from bench to bedside.

Wang, Ya-Tao; Ji, Wei-Dong; Jiao, Hong-Mei; Lu, Ang; Chen, Kun-Feng; Liu, Qi-Bing

Wang, Ya-Tao; Ji, Wei-Dong; Jiao, Hong-Mei; Lu, Ang; Chen, Kun-Feng; Liu, Qi-Bing.

Afiliación

Wang YT; First People's Hospital of Shangqiu, Henan Province, Shangqiu, China.
Ji WD; First People's Hospital of Shangqiu, Henan Province, Shangqiu, China.
Jiao HM; First People's Hospital of Shangqiu, Henan Province, Shangqiu, China.
Lu A; First People's Hospital of Shangqiu, Henan Province, Shangqiu, China.
Chen KF; First People's Hospital of Shangqiu, Henan Province, Shangqiu, China.
Liu QB; Department of Pharmacy, the First Affiliated Hospital of Hainan Medical University, Haikou, China.

Front Immunol ; 13: 975926, 2022.

Article en En | MEDLINE | ID: mdl-36189243

Asunto(s)

Inmunoterapia; Neoplasias; Miembro 9 de la Superfamilia de Receptores de Factores de Necrosis Tumoral/inmunología; Humanos; Ligandos; Receptores del Factor de Necrosis Tumoral; Microambiente Tumoral

Palabras clave

4-1BB; cancer; clinical trials; immune checkpoint inhibitor; immunotherapy

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Miembro 9 de la Superfamilia de Receptores de Factores de Necrosis Tumoral / Inmunoterapia / Neoplasias Límite: Humans Idioma: En Revista: Front Immunol Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google